{
  "docId": "019de070-701b-7388-a208-3e38cd293d9a",
  "docSlug": "f771dd63c4f3642a1d968d8585ded9c7",
  "documentTitle": "Evotec | Investor Day Presentation Deck | 103 slides",
  "authorId": "evotec",
  "authorName": "Evotec",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 103,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a chart showing mean relative change in cough frequency vs placebo across four dose levels.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-701b-7388-a208-3e38cd293d9a/35",
  "deckHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a",
  "deckJsonHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a.json",
  "deckAnchorHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.67,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Mean relative change in hourly cough frequency assessed over 24-hour periods versus placebo.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c1cc20a-cf3b-4c09-8d3a-ea0f21563568",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "list",
      "text": "Efficacy: Dose-dependent reduction in cough frequency over 24 hours; Daytime cough frequency reduction of 36% with 750 mg; Dose-dependent improvements in cough severity and LCQ",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08cc4f10-3d62-491f-b7bb-c9a9b09dbbe0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.03,
        "y": 0.3
      },
      "kind": "list",
      "text": "Safety: Low rates of AEs including taste-related AEs; All taste-related AEs mild and resolved after cessation of therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd186f55-87f7-47b7-a132-df68bd315094",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Status: Phase IIb initiated October 2020 – expected completion Q4/2021",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36d40068-845c-46af-8027-c1f2e65fb296",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1) Dose-dependent improvements in patients also seen in the Leicester Cough Questionnaire (LCQ). Sources: https://conference.thoracic.org/ Poster presented on the ATS 2020 International Conference Virtual Platform",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "380d7156-da34-4523-8c50-4e56a44e6d09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.25,
        "y": 0.1
      },
      "kind": "title",
      "text": "Phase II data support best-in-class potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0699f2d5-e2b8-41e3-8d5f-421a3676a8c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.25,
        "y": 0.17
      },
      "kind": "title",
      "text": "P2X3 antagonist – Eliapixant (BAY1817080) Refractory Chronic Cough (RCC)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99e66625-a4df-4448-958f-bcbc57a5729a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 50,
      "from": 31,
      "beatId": "26c91166-5be4-427d-a9a5-7b1df4f144e6",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The deck outlines Evotec's approach to precision medicine and co-owned clinical pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}